Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
Mohamed-Sami Trabelsi, Mehdi Daoudi, Janne Prawitt et al. · Nature Communications · 2015
Bile acids are signalling molecules, which activate the transmembrane receptor TGR5 and the nuclear receptor FXR. BA sequestrants (BAS) complex bile acids in the intestinal lumen and decrease intestinal FXR activity. The BAS–BA complex also induces glucagon-like peptide-1 (GLP-1) production by L cells which potentiates β-cell glucose-induced insulin secretion. Whether FXR is expressed in L cells and controls GLP-1 production is unknown. Here, we show that FXR activation in L cells decreases proglucagon expression by interfering with the glucose-responsive factor Carbohydrate-Responsive Element Binding Protein (ChREBP) and GLP-1 secretion by inhibiting glycolysis. In vivo, FXR deficiency increases GLP-1 gene expression and secretion in response to glucose hence improving glucose metabolism. Moreover, treatment of ob/ob mice with the BAS colesevelam increases intestinal proglucagon gene expression and improves glycaemia in a FXR-dependent manner. These findings identify the FXR/GLP-1 pathway as a new mechanism of BA control of glucose metabolism and a pharmacological target for type 2 diabetes. Bile acids exert metabolic effects by modulating FXR receptor activity. Here, Trabelsi et al.show that FXR negatively regulates production of the incretin GLP-1 in enteroendocrine L-cells by reducing glycolysis and that inhibition of FXR improves glucose metabolism by increasing GLP-1 in obese mice.
Cited by 400 works. doi:10.1038/ncomms8629 Open-access PDF
Authors
- Mehdi Daoudi
- Janne Prawitt
- Sarah Ducastel
- Véronique Touche
- Sama I. Sayin
- Alessia Perino
- Cheryl A. Brighton
- Yasmine Sebti
- Jérôme Kluza
- Olivier Briand
- Hélène Dehondt
- Emmanuelle Vallez
- Emilie Dorchies
- Grégory Baud
- Valeria Spinelli
- Nathalie Hennuyer
- Sandrine Caron
- Kadiombo Bantubungi
- Robert J. Caiazzo
References
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
- Biology of Incretins: GLP-1 and GIP
- Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes
- A G Protein-coupled Receptor Responsive to Bile Acids
- Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
- TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity
- Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
- Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice